Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Am J Physiol Endocrinol Metab 283:E1173E1177 Wynne K, Park AJ, Small CJ et al (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial
In the DURATION-8 trial, dapagliflozin as monotherapy and in combination with EX-QW showed trends favoring improvements in LFC, glucose and lipid metabolism, and liver fibrosis scores at the end of the study, but no significant statistical differences were observed
Palynological origin, phenolic content, and antioxidant properties of honeybee-collected pollen from Bahia, Brazil
Statistical analyses To describe the characteristics of patients in the cohort study, mean and standard deviation (SD) were presented for continuous data, and number ( n ) and percentage (%) were presented for categorical covariates
Any use for weight loss in a non-diabetic patient is considered off label and usually not covered by insurance
